Novartis (NVS)
(Delayed Data from NYSE)
$106.45 USD
-0.63 (-0.59%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $107.09 +0.64 (0.60%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.45 USD
-0.63 (-0.59%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $107.09 +0.64 (0.60%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
Zacks News
Teva Q2 Earnings Lag, '17 View & Dividend Cut, Stock Slumps
by Zacks Equity Research
Teva Pharmaceutical Industries Limited's (TEVA) Q2 earnings and missed expectations. It also slashed its 2017 earnings and sales outlook and cut its dividend by 75%.
Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits.
Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top
by Zacks Equity Research
Aduro (ADRO) incurs loss in Q2 but revenues beat estimates. However, the same declines year over year, courtesy a milestone payment from the year-ago quarter.
Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong
by Zacks Equity Research
Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.
Can Ligand (LGND) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.
Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) reported a narrower-than-expected loss in Q2 on the back of higher Ocaliva sales.
Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY
by Zacks Equity Research
The Medical sector has carried on the momentum of its first quarter performance so far this earnings season but lagged the overall market.
Roche's (RHHBY) Sales Grow Y/Y in 1H17 on New Drug Launches
by Zacks Equity Research
Roche Holdings (RHHBY) delivered an impressive performance in 1H17 driven by new drug launches.
Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura
by Zacks Equity Research
Ophthotech Corporation (OPHT) reported narrower-than-expected loss in the second quarter and also beat sales expectations.
What's in Store for Conatus (CNAT) this Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) aim to progress with its lead candidate emricasan might boost the stock in Q2 results, although the company's current portfolio shows no approved product and revenue generation.
Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.
Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY), Celgene (CELG) and Alexion Pharma (ALXN) are set to report second-quarter results on Jul 27.
Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK
by Zacks Equity Research
We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.
Foreign Stock Roundup: ABB, Novartis Beat on Earnings
by Swarup Gupta
Global markets were weighed down by comments from the ECB and Bank of Japan even as bullish GDP data emerged from China this week
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
by Zacks Equity Research
Three pharma giants are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen, Inc.'s (AMGN) growth drugs like Prolia & Xgeva might continue to do well. Biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval
by Zacks Equity Research
Puma Biotechnology, Inc's (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx.
Ligand Signs Agreement with Amgen, Grants Rights to Captisol
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) announced that it has signed a commercial license and supply agreement with Amgen Inc. granting exclusive worldwide rights to use Ligand's Captisol technology for the development of AMG 330
Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure
by Zacks Equity Research
Novartis AG (NVS) reported second-quarter 2017 core earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 but the recorded figure was a penny lower than the year-ago figure of $1.23.
5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote
by Arpita Dutt
It's time to look at these 5 CAR-T stocks given the interest generated by a positive FDA advisory panel vote for Novartis' (NVS) experimental CAR-T treatment.
4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings
by Arpita Dutt
Here is a look at four drug stocks including Anika (ANIK) with a Sell Rank and negative earnings ESP that should be avoided ahead of earnings.
J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.
Can Novartis (NVS) Spring a Surprise This Earnings Season?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.
Novartis CAR-T Therapy Drug Recommended by FDA Panel
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has unanimously (10-0) recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel).
Can ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth?
by Zacks Equity Research
On Jul 12, 2017, we issued an updated report on ImmunoGen, Inc. (IMGN).